Application of dexlansoprazole to broaden therapeutic options for gastroesophageal reflux disease
About the Authors
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
R. A. Abdulkhakov
State educational government-financed institution of higher professional education «Kazan State Medical University»
Russian Federation
Russian Federation
O. P. Alekseyeva
Gastroenterology center, Semashko Nizhny Novgorod regional clinical hospital
Russian Federation
Russian Federation
S. A. Alekseyenko
State educational government-financed institution of higher professional education «Far East state medical university»
Russian Federation
Russian Federation
N. V. Zakharova
State educational government-financed institution of higher professional education «Mechnikov North-Western State Medical University»
Russian Federation
Russian Federation
N. V. Korochanskaya
Federal state-funded healthcare institution Regional hospital #2, Ministry of Healthcare of Krasnodar region
Russian Federation
Russian Federation
I. L. Klyaritskaya
State educational autonomous institution of higher education «Vernadsky Crimea Federal University»
Russian Federation
Russian Federation
I. V. Mayev
State educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
M. F. Osipenko
State educational government-financed institution of higher professional education «Novosibirsk state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. I. Simanenkov
State educational government-financed institution of higher professional education «Mechnikov North-Western State Medical University»
Russian Federation
Russian Federation
A. V. Tkachev
State educational government-financed institution of higher professional education «Rostov state medical university»,
Ministry of healthcare of the Russian Federation
Russian Federation
Russian Federation
A. S. Trukhmanov
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
I. B. Khlynov
State educational government-financed institution of higher professional education «Ural state medical university»,
Ministry of healthcare of Russia
Russian Federation
Russian Federation
References
1. Ивашкин В.Т., Шептулин А.А., Трухманов А.С., Маев И.В., и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации по диагностике и лечению. М., 2014:31 с.
2. Инструкция по применению лекарственного препарата для медицинского применения Дексилант®. Регистрационное удостоверение ЛП 002477.
3. Лазебник Л.Б., Машарова А.А., Бордин Д.С., и др. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России (МЭГРЕ): первые итоги. Эксп клин гастроэнтерол 2009; 6:4-12.
4. Маев И.В., Вьючнова Е.С., Щекина М.И. Гастроэзофагеальная рефлюксная болезнь – болезнь XXI века. Лечащий врач 2004; 4:10-4.
5. Номера патентов: 6,664,276 15 December 2020; 6,939,971 15 December 2020.
6. Осипенко М.Ф., и др. Комплайнс: определяющие факторы и пути оптимизации приверженности к лечению. Сибирское мед обозрение 2010; 5:94-7.
7. Симаненков В.И., Тихонов С.В. Поддерживающее лечение у пациентов с гастроэзофагеальной рефлюксной болезнью. Фарматека. Гастроэнтерология/Гепатология 2014; 2:1-6.
8. Шептулин А.А. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол 2010; 20(6):81-5.
9. Bardhan K.D. Am J Gastroenerol 2003; 98 (3):40-8.
10. Behm B.W., Peura D.A. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2011; 5:439-45.
11. Chey W.D., et al. Dig Dis Sci 2010; 55:3415-22.
12. Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19(39):6529-35.
13. Dent J., et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53 (Suppl. 4):1-24.
14. Dent J., El-Serag H.B., Wallander M.A., Johansson S. Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2005; 54:710-7.
15. Domingues G., Moraes-Filho J.P. Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2014; 8(7):761-5.
16. El-Serag H., Hill C., Jones R. Systematic review: the epidemiology of gastroesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther 2008; 29:470-80.
17. Farmer K.C. Medication adherence in health care: are we utilizing what we have learned? Clin Ther 2011; 33(8):1081-3.
18. Fass R., Inadomi J., Han C., et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol 2012; 10:247-53.
19. Fock K., et al. Gastroenterol Hepatol 2008; 23(1):8-22.
20. Gallup Organization. The 2000 Gallup Study of Consumers’ Use of Stomach Relief Products. Princeton: Gallup Organization; 2000.
21. Gunaratnam N.T., et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastroesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473-7.
22. Hungin A.P., et al. Br J Gen Practice 1999; 49:463-4.
23. Hungin A.P., et al. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10(2):109-16.
24. Katsuki H., et al. Determination of R(+)and S(-)lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans Pharm Res 1996; 13(4):611-5.
25. Katz P.O., et al. Am J Gastroenterol 2013; 108:308-28.
26. Kukulka M., Eisenberg C., Nudurupati S. Comparator pH study to evaluate the singledose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol 2011; 4:213-20.
27. Lee R., Mulford D., Wu J., Atkinson S. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther 2010; 31:1001-11.
28. Lee R., Vakily M., Mulford D., Wu J., Atkinson S. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility. Aliment Pharmacol Ther 2009; 29:824-33.
29. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5):487-97.
30. Sabate E. Adherence to long-term therapies. Evidence for action. Geneva, Switzerland: World Health Organization, 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html
31. Tutuian R., Katz P.O., Castell D.O. Nocturnal acid breakththrough, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16:441-63.
Review
For citations:
Ivashkin V.T., Abdulkhakov R.A., Alekseyeva O.P., Alekseyenko S.A., Zakharova N.V., Korochanskaya N.V., Klyaritskaya I.L., Mayev I.V., Osipenko M.F., Simanenkov V.I., Tkachev A.V., Trukhmanov A.S., Khlynov I.B. Application of dexlansoprazole to broaden therapeutic options for gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):120-123. (In Russ.)
Views:
98
Email this article 
